trending Market Intelligence /marketintelligence/en/news-insights/trending/Y2vM4ZiaPFS1o_reDOrFew2 content esgSubNav
In This List

AstraZeneca appoints nonexecutive director

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


AstraZeneca appoints nonexecutive director

AstraZeneca PLC said it appointed Michel Demaré to be a nonexecutive director and a member of its audit committee, effective Sept. 1.

Demaré was vice chairman of UBS Group AG from 2010 to 2019. He also served as CFO of Switzerland's ABB Ltd., an electrical equipment company, from Jan. 1, 2005, to Jan. 31, 2013.

Before that, he was CFO for Europe operations and vice president at Deerfield, Ill.-based healthcare equipment company Baxter International Inc. from 2002 to 2005.

Demaré is also a nonexecutive director of Vodafone Group PLC and a member of the supervisory board of Louis Dreyfus Commodities Holdings BV.

U.K.-based drugmaker AstraZeneca develops medicines to treat various kinds of cancer, respiratory illnesses and cardiovascular, renal and metabolism-related diseases.